Browsing by Author "İdilman, Ramazan"
Now showing 1 - 7 of 7
- Results Per Page
- Sort Options
Item Association between level of hepatitis d virus RNA at week 24 of pegylated interferon therapy and outcome(Elsevier, 2015-12) Keskin, Onur; Wedemeyer, Heiner; Tüzün, Ali; Zachou, Kalliopi; Deda, Xheni; Dalekos, George N.; Heidrich, Benjamin; Pehlivan, Selcen; Zeuzem, Stefan; Yalçın, Kendal; Tabak, Fehmi; İdilman, Ramazan; Bozkaya, Hakan; Manns, Michael; Yurdaydın, Cihan; Gürel, Selim; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; 7003706434BACKGROUND & AIMS: Interferon is the only effective treatment for chronic hepatitis D virus (HDV) infection. No rules have been set for stopping treatment based on viral kinetics. We analyzed data from an international study of hepatitis D treatment to identify factors associated with outcomes of pegylated interferon treatment, with and without adefovir. METHODS: We analyzed data from the Hep-Net-International Delta Hepatitis Intervention Trial on 50 patients with compensated liver disease who tested positive for anti-HDV and HDV RNA. Subjects received pegylated interferon alpha 2a, with adefovir or placebo, or only adefovir, for 48 weeks. Twenty-four weeks after treatment ended, 41 patients were evaluated for levels of HDV RNA and DNA, liver enzymes, and hepatitis B surface antigen (HBsAg); liver biopsy specimens were analyzed for fibrosis. Response to therapy was defined as end-of-treatment response or post-treatment week 24 virologic response. In both cases virologic response was associated with undetectable HDV RNA levels. Patients with less than a 1 log decrease in HDV RNA at the end of treatment were considered null responders. RESULTS: Based on univariate and multivariate analysis, the level of HDV RNA at week 24 of treatment was associated more strongly with response to therapy than other factors analyzed. The level of HBsAg at week 24 of treatment was associated with a response to therapy only in univariate analysis. Lack of HDV RNA at week 24 of treatment, or end of treatment, identified responders with positive predicted values of 71% and 100%, respectively. At 24 weeks after treatment, a decrease in HDV RNA level of less than 1 log, combined with no decrease in HBsAg level, identified null responders with a positive predictive value of 83%. A decrease in HDV RNA level of more than 2 log at week 24 of treatment identified null responders with a negative predictive value of 95%. CONCLUSIONS: Based on an analysis of data from a large clinical trial, the level of HDV RNA at week 24 of treatment with pegylated interferon, with or without adefovir for 48 weeks, can identify patients who will test negative for HDV RNA 24 weeks after the end of treatment. This information can be used to help physicians manage patients receiving therapy for chronic hepatitis D.Publication Covid-19 in liver transplant recipients: A national cohort(Elsevier, 2021-07-01) Kabaçam, Gökhan; Turan, İlker; Kiyici, Murat; Ellik, Zeynep Melekoğlu; Dolu, Süleyman; Dayanğaç, Murat; Arı, Derya; Gökçe, Dilara Turan; Yıldırım, Abdullah Emre; Gençdal, Genco; Harputluoğlu, Murat; Kartal, Aysun; Demiray, Emine Kübra Dindar; Gündüz, Feyza; Ergenç, İlkay; Efe, Cumali; Sümer, Hale Gökcan; Kayhan, Meral Akdoğan; Gülşen, Murat Taner; Akyıldız, Murat; Arıkan, Çiğdem; Karademir, Sedat; Balcı, Deniz; Dündar, Ziya; Akarsu, Mesut; Günşar, Fulya; Karasu, Zeki; İdilman, Ramazan; KIYICI, MURAT; DÜNDAR, HALİT ZİYA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.; FHW-0015-2022; JHK-0911-2023Publication Efficacy and safety of tenofovir alafenamide in hepatitis B virus-infected patients with chronic hemodialysis and renal transplantation: A preliminary result(Lippincott Williams & Wilkins, 2021-10-01) Adanır, Haydar; Etik, Diğdem Özer; Yıldırım, Abdullah Emre; Mehdiyev, Shahin; Yapalı, Suna; Coşar, Arif Mansur; Arı, Derya; Gökcan, Hale; Teker, Tufan; Kıyıcı, Murat; Balaban, Yasemin Hatice; Alkım, Hüseyin; Üçbilek, Enver; Ünsal, Yasemin; Harputluoğlu, Murat; Vatansever, Sezgin; Demir, Mehmet; Güzelbulut, Fatih; Gündüz, Feyza; Boyacıoğlu, Sedat; Bilgiç, Yılmaz; Ekmen, Nergis; Arslan, Mehmet; Şimşek, Halis; Akdoğan, Meral; Dinçer, Dinç; Tozun, Nurdan; İdilman, Ramazan; TEKER, TUFAN; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; EAB-6931-2022; FHW-0015-2022Publication Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort(Wiley, 2019-06-01) İdilman, Ramazan; Demir, Mehmet; Aladağ, Murat; Erol, Cihan; Çavuş, Bilger; İliaz, Raim; Köklü, Hayrettin; Çakaloğlu, Yılmaz; Şahin, Memduh; Ersöz, Galip; Köksal, İftihar; Karasu, Zeki; Özgenel, Meriç; Turan, İlker; Gündüz, Feyza; Ataseven, Hüseyin; Akdoğan, Meral; Kıyıcı, Murat; Köksal, Aydın Şeref; Akhan, Sila; Günsar, Fülya; Tabak, Fehmi; Kaymakoglu, Sabahattin; Akarca, Ulus S.; Akarsu, Mesut; Alkim, Hüseyin; Araz, Filiz; Ateş, Fehmi; Aygen, Bilgehan; Balık, İsmail; Barut, Hüseyin S.; Baysal, Birol; Bolat, Aylin; Çelik, İlhami; Coşgun, Süleyman; Ensaroglu, Fatih; Gökcan, Hale; Gürel, Selim; Gürsoy, Şebnem; İnkaya, Ahmet Çağan; Kamilli, Cemil; Kav, Taylan; Kuruüzüm, Ziya; Önder, Fatih O.; Örmeci, Necati; Özbakır, Ömer; Özenirler, Seren; Özer, Birol; Özkan, Hasan; Poturoğlu, Şule; Senates, Ebubekir; Şimşek, Halis; Toka, Bilal; Ünal, Hakan; Yaras, Serkan; Yıldırım, Abdullah E.; Yıldırım, Beytullah; Yılmaz, Bülent; Yılmaz, Hasan; Yozgat, Ahmet; Yurdaydın, Cihan; Early Access Program EAP Study Grp; KIYICI, MURAT; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı; 0000-0002-3208-6211; AAI-4213-2021The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.Item Pegylated-Interferon-a-2a plus Tenofovir or Placebo for the treatment of hepatitis delta: First results of the HIDIT-2 study(Wiley, 2012-10) Yurdaydın, Cihan; Wedemeyer, Heiner; Caruntu, Florin A.; Curescu, Manuela G.; Yalçın, Kendal; Akarca, Ulus S.; Zeuzem, Stefan; Erhardt, Andreas; Lueth, Stefan; Papatheodoridis, George V.; Port, Kerstin; Keskin, Onur; Radu, Monica N.; Çelen, Mustafa K.; İdilman, Ramazan; Stift, Judith; Mederacke, Ingmar; Heidrich, Benjamin; Manns, Michael P.; Dienes, Hans Peter; Gürel, Selim; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.; 0000-0002-7279-2161; EYK-5719-2022Item Recurrence and occurrence of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment for chronic hepatitis C in patients with advanced liver disease: Turkish multi-center early access program(Elsevier, 2018-04) İdilman, Ramazan; Demir, Mehmet; Aladağ, Murat; Kaymakoğlu, Sabahattin; Erol, Cihan; Çavuş, Bilger; İliaz, Raim; Akarca, Ulus S.; Köklü, Seyfettin; Çakaloğlu, Yılmaz; Şahin, M.; Köksal, I.; Özgenel, Meriç; Toka, Bilal; Karasu, Zeki; Ersöz, Galip; Akdoğan, Meral; Kıyıcı, Murat; Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.; AAI-4213-2021Item Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study(Wiley, 2020-11-20) Bremer, Birgit; Anastasiou, Olympia E.; Hardtke, Svenja; Caruntu, Florin A.; Curescu, Manuela G.; Yalçın, Kendal; Akarca, Ulus S.; Zeuzem, Stefan; Erhardt, Andreas; Luth, Stefan; Papatheodoridis, George V.; Radu, Monica; İdilman, Ramazan; Manns, Michael P.; Cornberg, Markus; Yurdaydın, Cihan; Wedemeyer, Heiner; Gürel, Selim; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları.; HLH-8209-2023; 7003706434The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.